External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease

BACKGROUND: Recent treatment guidelines support the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes and cardiovascular disease based on the results of cardiovascular outcome trials (CVOTs). Applicability of these trials to everyday patients with type 2 diab...

Descripción completa

Detalles Bibliográficos
Autores principales: Smidt, Lisanne C. A., Visseren, Frank L. J., de Ranitz-Greven, Wendela L., Nathoe, Hendrik M., Kappelle, L. Jaap, de Borst, Gert J., de Valk, Harold W., Westerink, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427950/
https://www.ncbi.nlm.nih.gov/pubmed/34496847
http://dx.doi.org/10.1186/s12933-021-01373-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427950/
https://www.ncbi.nlm.nih.gov/pubmed/34496847
http://dx.doi.org/10.1186/s12933-021-01373-9

Ejemplares similares